Browse IL2RG

Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF09240 Interleukin-6 receptor alpha chain
Function

Common subunit for the receptors for a variety of interleukins.

> Gene Ontology
 
Biological Process GO:0035771 interleukin-4-mediated signaling pathway
GO:0038110 interleukin-2-mediated signaling pathway
GO:0038111 interleukin-7-mediated signaling pathway
GO:0070669 response to interleukin-2
GO:0070670 response to interleukin-4
GO:0071352 cellular response to interleukin-2
GO:0071353 cellular response to interleukin-4
GO:0098760 response to interleukin-7
GO:0098761 cellular response to interleukin-7
Molecular Function GO:0004896 cytokine receptor activity
GO:0004911 interleukin-2 receptor activity
GO:0004913 interleukin-4 receptor activity
GO:0004917 interleukin-7 receptor activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0019976 interleukin-2 binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04144 Endocytosis
hsa04151 PI3K-Akt signaling pathway
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL2RG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL2RG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22981349Kidney carcinomaPromote immunityRecent data highlight new functions of IL-15 in renal homeostasis mediated by IL-15Rγ (CD132). In renal cancer, loss of CD132 by epithelial cells defines a tumoral microenvironment where IL-15 triggers E-cadherin down-regulation and EMT. Finally, in CD132+ renal cancer stem cells IL-15 induces the generation of non-tumorigenic epithelial cells sensitive to cytotoxic drugs.
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL2RG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL2RG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0020.997
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2060.919
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1510.924
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6020.259
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1740.894
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1540.534
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8250.189
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2430.394
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3770.814
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.5510.168
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0740.485
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.040.849
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL2RG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL2RG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL2RG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL2RG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL2RG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL2RG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL2RG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL2RG
Nameinterleukin 2 receptor, gamma
Aliases CD132; SCIDX1; IMD4; CIDX; severe combined immunodeficiency; combined immunodeficiency, X-linked; IL-2RG; P6 ......
Chromosomal LocationXq13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL2RG collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL2RG.
ID Name Drug Type Targets #Targets
DB00004Denileukin diftitoxBiotechIL2RA, IL2RB, IL2RG3
DB00041AldesleukinBiotechIL2RA, IL2RB, IL2RG3
DB05943ResatorvidSmall MoleculeCSF2RB, IL2RG2